ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Alnylam Pharmaceuticals and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Alnylam PharmaceuticalsAbbVie
studies on the registry842,251
open to participants now18133
phase 3 studies under way574
reach primary completion within a year890
programswith a study of their own in two years1170+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAlnylam PharmaceuticalsAbbVie
Phase 1

Alnylam Pharmaceuticals: 4 of its 11 programs at phase 1

  1. ALN-4285phase 1
  2. ALN-4915phase 1
  3. ALN-5288phase 1
  4. ALN-6222phase 1
36%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

Alnylam Pharmaceuticals: 5 of its 11 programs at phase 2

  1. mivelsiranphase 2
  2. ALN-4324phase 2
  3. ALN-6400phase 2
  4. ALN-AGT01 RVRphase 2
  5. ALN-2232phase 2
45%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

Alnylam Pharmaceuticals: 2 of its 11 programs at phase 3

  1. nucresiranphase 3
  2. zilebesiranphase 3
18%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies00%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Alnylam Pharmaceuticals6 readouts · 0 phase 3·

Alnylam Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. ALN-4285phase 1 · Dec 29 · NCT07295717
···

Alnylam Pharmaceuticals, Apr ’27: 1 program whose next study reaches primary completion

  1. ALN-2232phase 2 · Apr 28 · NCT07463846

Alnylam Pharmaceuticals, May ’27: 1 program whose next study reaches primary completion

  1. ALN-4324phase 2 · May 28 · NCT07465224

Alnylam Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion

  1. ALN-6400phase 2 · Jun 30 · NCT07575308

Alnylam Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion

  1. ALN-4915phase 1 · Jul 31 · NCT07535606

Alnylam Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion

  1. mivelsiranphase 2 · Aug 9 · NCT06393712
··
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Alnylam Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionAlnylam PharmaceuticalsAbbVie
Alzheimer Diseaseboth · compare here

Alnylam Pharmaceuticals in Alzheimer Disease: 2 programs

  1. mivelsiranphase 2
  2. ALN-5288phase 1

Their studies: Alnylam Pharmaceuticals’ studies of Alzheimer Disease in search

AbbVie in Alzheimer Disease: 3 programs

  1. emraclidinephase 2
  2. ABBV-1758phase 2
  3. ALIA-1758phase 1

Their studies: AbbVie’s studies of Alzheimer Disease in search

Obesityboth · compare here

Alnylam Pharmaceuticals in Obesity: 3 programs

  1. ALN-4324phase 2
  2. ALN-2232phase 2
  3. ALN-6222phase 1

Their studies: Alnylam Pharmaceuticals’ studies of Obesity in search

AbbVie in Obesity: 1 program

  1. ABBV-295phase 2

Their studies: AbbVie’s studies of Obesity in search

Amyloidosisboth · compare here

Alnylam Pharmaceuticals in Amyloidosis: 1 program

  1. nucresiranphase 3

Their studies: Alnylam Pharmaceuticals’ studies of Amyloidosis in search

AbbVie in Amyloidosis: 1 program

  1. etentamigphase 3

Their studies: AbbVie’s studies of Amyloidosis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Alnylam Pharmaceuticals 0 of 11 · AbbVie 54 of 70 programs (13 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8).